Lɛ wi lan bɔt DLBCL (Diffuse Large B-Cell Lymphoma) kansa insay wan simpul we.

Yu dɔn ɛva yɛri bɔt di sik we dɛn kɔl `Diffuse Large B-Cell Lymphoma` ɔ `DLBCL`? Dis na wan kayn kansa wae kin skata kwik kwik wan. Bɔt nɔ wɔri, if dɛn no am kwik ɛn trit am kɔrɛkt wan , i kin mɛn . Tide, lɛ wi tɔk bɔt dis `DLBCL` insay simpul wɔd dɛn.

Wetin na DLBCL?

DLBCL na kansa we de na di blɔd. Insay dis sik, wan kayn wayt blɔd sɛl we dɛn kɔl B sɛl (we dɛn kin kɔl bak limfosayt) na wi bɔdi kin bi kansa. dis na di kayn limfoma we kכmכn, we de gro fast fast, εn we de agresiv we dεn kכl non-Hodgkin lymphoma. Wi limfatik sistɛm de fɛt di jem dɛn. we DLBCL de divεlכp, dεn B sεl dεm ya kin bi kεnsar εn gro kwik kwik wan, we kin kכl di hεlty sεl dεm. Dɔn dɛn nɔ kin ebul fɔ fɛt di jem dɛn. Dɛn kansa sɛl ya kin fɔm ɛnisay, lɛk di limf no dɛm, di dijestiv trakt, ɛn di bren. Pan ɔl we i siriɔs, i kin mɛn if dɛn no am kwik.

Wetin na di kayn DLBCL?

Di Wol Ɛlth Ɔganayzeshɔn (WHO) dɔn no bɔku kayn DLBCL. Dɔktɔ dɛn kin yuz ɛni kayn kansa fɔ no aw di kansa kin go bifo ɛn aw i kin biev we dɛn gɛt tritmɛnt. Dis klasification de mainly influenced by:

• di chenj dεm we de apin na di jεnεtiks na di sεl dεm.
• di lכkεshכn na di bכdi usay DLBCL de bigin (e.g., sεntri nεv sεstem - `CNS`).
• wan asosieshכn wit wan vayrus (e.g. Epstein-Barr vayrus - EBV).

I rili impɔtant fɔ aks yu dɔktɔ bɔt di kayn DLBCL we yu gɛt.

Aw kɔmɔn tin dis?

DLBCL na di kayn limfoma we kin kכmכn pas כl . Bɔt DLBCL nɔ kin rili kɔmɔn pan kansa dɛn in jɛnɛral. Fɔ ɛgzampul, DLBCL kin apin to lɛk 6 pan ɛvri 100,000 pipul dɛm. Dis nɔ kin apin so ɔltɛm we yu kɔmpia am to ɔda kansa dɛn.

Wetin na di sayn dɛm fɔ DLBCL?

Di sayn we kin sho se pɔsin gɛt DLBCL na we di limf no dɛn we de swel na di nɛk, di an, ɔ di groin . Dɛn tin ya kin bigin lɛk wan smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl.

Sɔm pipul dɛm (lɛk wan pan tri pipul dɛm) kin gɛt spɛshal sayn dɛm bak we dɛn kɔl "B simptom dɛm" :

• Fiva (we pas 39.5 sɛlshiɔs) we kin las fɔ pas tu dez ɔ we kin kam ɛn go.
• Fɔ lɔs pas 10% pan di bɔdi wet insay siks mɔnt we nɔ gɛt ɛni rizin.
• Swet bɔku na nɛt, so dat di bedshit dɛn kin wet.

Nɔr frayd fɔ tink se na DLBCL ivin if yu gɛt dɛn sik ya. Bɔt if dɛn kɔntinyu fɔ de fɔ sɔm wiks, go to dɔktɔ.

Wetin mek DLBCL de divɛlɔp? Wetin na di tin dɛn we kin mek pɔsin gɛt dis sik?

DLBCL de kכz bay mכtεshכn dεm na di B sεl dεm. Dis na di jεnεtik mכtεshכn dεm we dεn kin gεt we kin apin we dεn de liv . Wi nɔ no di rayt tin we kin mek i apin, bɔt dɛn dɔn no bɔku tin dɛn we kin mek di sik bɔku:

• Ej:E kin bɔrku pan pipul dɛm wae dɔn pas 60 ia. Di avrej ej fɔ no di sik na lɛk 64 ia.
• Jɛnda: Man dɛn kin gro smɔl pas uman dɛn.
• Famili histri: If yu fambul we de na yu fɔs digri (mama ɔ papa, brɔda ɛn sista, pikin) gɛt DLBCL, yu kin gɛt smɔl risk fɔ gɛt am (di rizin nɔ klia yet).
• Infεkshכn: Vayrus dεm lεk Epstein-Barr vayrus (EBV), human immunodeficiency virus (HIV), εn epataytis B εn C.
• di imyun sistεm we wik: fכ gεt `primary immunodeficiency` כ `autoimmune disorder`, כ fכ tek `immunosuppressants` afta dεn transplant yu כgan. Dis na big tin we kin mek pɔsin gɛt prɔblɛm.
• di hכy bכdi mas indeks (BMI) we i yכng εn we i de εkspos to sכ m tכxik tin dεm we dεn kin yus fכ fam.

Pan ɔl we dɛn tin ya de, nɔto ɔlman kin gɛt dɛn, ɔ dɛn kin gɛt dɛn. Bɔt i impɔtant fɔ no bɔt dɛn tin ya.

Aw dɛn kin no DLBCL? (Diagnosis) .

di dכkta dεm kin kכnfכm DLBCL tru wan limf node bayopsi (we dεn tek wan sכm pat pan wan limf node we swel fכ egzamin) εn jεnεtik tεst. If dɛn kɔnfyus DLBCL, dɛn kin du ɔda tɛst fɔ si if di kansa dɔn skata:

• Blɔd tɛst: Kɔmplit blɔd kɔnt (CBC), fɔ chɛk fɔ vayrɔs lɛk HIV, EBV, ɛn epataytis.
• Laktat dihaydrojenεz (LDH) tεst: dis εnzym de fכn na hכy lεvεl insay di mכtalman DLBCL pasεnshכn dεm.
• Imej tɛst: CT skan, MRI skan, PET skan.
• `Bɔn mɛrɔ bayɔpsi` .
• Lumbar pankshכn (εgzamεn fכ di spεnal fכluid).

Dɔktɔ dɛn kin disayd bɔt yu sik ɛn plan tritmɛnt bay di infɔmeshɔn we dɛn kin gɛt frɔm ɛni wan pan dɛn tɛst ya.

Wetin na di stej dɛm fɔ DLBCL?

Dɛn kin yuz kansa stej sistɛm fɔ no aw fa kansa dɔn gro ɛn spre. Dis kin ɛp fɔ plan di tritmɛnt ɛn prɛdikt di prɔgnosis. Di stej dɛm fɔ DLBCL na:

• Stej I: Di kansa de nכmכ na wan limf node, wan כgan na di limf sistεm, כ wan εria na wan כgan we de ausayd di limf sistεm.
• Stej II: Limfoma de insay sεvεra grup dεm fכ limf no dεm na di sem say na di dayafragm.
• Stej III: Kansa de na di limf no dεm na di tu say dεm na di dayafragm.
• Stej IV: .DLBCL kansa dεn dכn spre to כgan dεm we de autsay di limfatik sistεm (e.g. bon mכro, liva, lכng).

dכkta dεn kכl stej I εn II "εli stej dεm" εn stej III εn IV "advans stej dεm."

Wetin na di tritmɛnt dɛm fɔ DLBCL?

Di tritmɛnt we dɛn kin yuz mɔ fɔ DLBCL na R-CHOP . Dis involv wan kɔmbaynshɔn fɔ wan monoklɔnal antibodi we dɛn kɔl rituximab, sɔm kayn kemotɛrapi, ɛn wan kɔtikosterɔyd. Ivin if dis tritmɛnt dɔn wok fayn, di sik kin kam bak (lɛk 30%-40%). If dis apin, yu dɔktɔ kin tɛl yu fɔ du ɔda tritmɛnt dɛn:

• Sεkכn layn tritmεnt εn `autologous stεm sεl transplant`.
• `CAR T-sεl tεrapi`: Dis na `imyunכtεrapi`.
• `Targeted therapy`: Tritmεnt dεm we de tכk bכt jεnεtik chenj dεm.

Mɛmba se yu dɔktɔ go disayd di bɛst tritmɛnt fɔ yu bay di patikyula sik we yu gɛt.

Yu tink se dɛn kin stɔp di divɛlɔpmɛnt fɔ DLBCL?

No we nɔ de fɔ mek dɛn nɔ gɛt DLBCL kpatakpata. Sɔm tin dɛn de we kin mek wi nɔ ebul fɔ kɔntrol. Bɔt sɔm tin dɛn de we wi kin du fɔ protɛkt wisɛf frɔm infɛkshɔn dɛn we kin gɛt fɔ du wit DLBCL, lɛk epataytis ɛn HIV. I fayn bak fɔ tray fɔ mek yu gɛt wɛlbɔdi bɔdi mas indeks (BMI). Dɛn tin ya kin ɛp fɔ ridyus yu risk to sɔm mak.

Wetin pɔsin we gɛt DLBCL kin ɛkspɛkt?

Sɔm kayn DLBCL kin mek pɔsin in layf de pan denja ɛn i nɔ kin izi fɔ trit. Bɔt bɔku tɛm, dɔktɔ dɛn kin ebul fɔ mɛn di sik ɛn mɛn am . Bɔrku tɛm, frɔnt layn tritmɛnt kin briŋ DLBCL to kɔmplit rɛmishɔn (wan stet usay nɔr sayn ɔr simptom nɔr de fɔ di kansa). Na lɛk 60% pan di pipul dɛm wae gɛt DLBCL kin wɛl wit fɔs layn tritmɛnt. Na avrej, pipul dɛm wae nɔr gɛt kansa tu ia afta dɛn dɔn no bɔt dɛn sik kin ɛkspɛkt fɔ liv nɔrmal layf, lɛk ɔda pipul dɛm wae gɛt dɛn ej. Di rεt fɔ liv kin ivin hεvi if dεn dεtekt kansa na di εli stej .

Bɔt yu ɛkspiriɛns go dipen pan bɔku tin, lɛk di kayn DLBCL we yu gɛt, di stej we di kansa de, ɛn yu ɔl wɛlbɔdi. Na yu dɔktɔ nɔmɔ go ebul fɔ gi yu di bɛst infɔmeshɔn bɔt dis.

Aw a kin kia fɔ misɛf? (Fɔ kia fɔ yusɛf) .

Fɔ liv wit kansa nɔr izi, i kin rili taya. I rili impɔtant fɔ tek kia ɔf yusɛf we yu de du tritmɛnt fɔ `DLBCL`.

• Nyutrishɔn: It gud it we balans. Aks yu dɔktɔ wetin fɔ it ɛn wetin fɔ avɔyd.
• Rɛst:Di tritmɛnt kin mek yu taya. Gɛt bɔku rɛst.
• Ɛksesaiz: Fɔ ɛksesaiz layt kin mek yu nɔ strɛs.
• Sɔpɔt: Dis na tin wae nɔr kin bɔrku, so e kin fil lɛk yu wan. Join sɔpɔt grup dɛn usay pipul dɛn lɛk yu de. Tɔk to yu fambul ɛn padi dɛn.

Nid fɔ go to dɔktɔ ɛn imejensi

Yu go si yu dɔktɔ ɔltɛm we yu de du tritmɛnt. Ivin afta di tritmɛnt dɔn, yu go nid fɔ si am ɛvri 3-4 mɔnt fɔ di fɔs tu ia ɛn nɔto so fɔ di nɛks tri ia. Dis na fɔ chɛk fɔ si if i de kam bak. If yu gɛt ɛni sayn fɔ sho se di kansa dɔn kam bak, tɛl yu dɔktɔ wantɛm wantɛm.

Tritmɛnt lɛk kemotɛrapi kin gɛt siriɔs sayd ɛfɛkt. If dɛn tin ya apin , go na imejensi rum wantɛm wantɛm :

• Mɔ bad bad sayd ɛfɛkt dɛn pas aw dɛn bin de tink.
• Fiva we pas 38 Sɛlshiɔs (100.4 Fɛnayt).
• Shek we pɔsin nɔ go ebul fɔ stɔp .
• Bɛlɛ pen bad bad wan ɔ dayarɛa we nɔ de dɔn .

Kwɛshɔn fɔ aks yu dɔktɔ bɔt DLBCL

Na nɔmal tin fɔ gɛt bɔku kwɛstyɔn we yu kam fɔ no se yu gɛt DLBCL. I impɔtant fɔ mek yu aks yu dɔktɔ kwɛstyɔn dɛn lɛk dɛn wan ya:

• Us kayn `Diffuse Large B-Cell Lymphoma` a gɛt? Wetin na di `stej`?
• Us kayn tritmɛnt a nid? Wetin na di bad tin dɛn we kin apin to pɔsin?
• Yu tink se dɛn tritmɛnt ya go mɛn kansa kpatakpata?
• Us tritmɛnt dɛn de if di kansa kam bak?
• Yu kin rifer mi to sɔpɔt grup fɔ pipul dɛn we gɛt dis kayn kansa?

Apat frɔm dɛn kwɛstyɔn ya, nɔ fred fɔ aks yu dɔktɔ ɛnitin we yu gɛt na yu maynd ɔ ɛni dawt we yu gɛt.

Fɔ dɔn, mɛmba (Take-Home Message) .

We bɔku pan wi kin yɛri di wɔd "aggressive" we wi de tɔk bɔt kansa, wi kin tink bɔt am as sik we nɔ go mɛn ɛn we at fɔ mɛn. Bɔt nɔto so i kin bi wit Diffuse Large B-Cell Lymphoma (DLBCL). Pan ɔl we DLBCL kin skata kwik kwik wan, di tritmɛnt dɛn we dɛn de gi kansa naw kin kil dɛn kansa B sɛl ya bɔku tɛm. Dɔktɔ dɛn kin ivin yuz wɔd dɛn lɛk "cure" we dɛn de tɔk bɔt sɔm pipul dɛn kɔndishɔn.

De tin wae impɔtant pas ɔl na fɔ aks yu dɔktɔ aw di sik wae yu gɛt go afɛkt aw yu de si aw fɔ trit yu. So, nɔ fred, mek dɛn no bɔt yu, ɛn fala yu dɔktɔ in advays. Nɔ fɔgɛt se dɛn kin win DLBCL if dɛn no am kwik ɛn trit am fayn!

` Kansa, limfoma, B sɛl, limf no dɛm, simptom dɛm, tritmɛnt, DLBCL, kemotɛrapi, imyunotɛrapi